Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...

Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic ...

Eli Lilly ( LLY) is expected to see a multi-fold increase in its earnings during its third quarter earnings, which is scheduled for October 29 after markets close. The pharma giant is expected to ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, ...

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3, with ...